Biofrontera

Biofrontera EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -11.84. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -13.61 — a change of -12.95% (higher).

EV/EBITDA

-11.84

YoY

-12.95%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Biofrontera is 2025 -11.84 . EV/EBITDA (Enterprise Value to EBITDA) of Biofrontera was 2024 -13.61 . It decreases by -12.95% higher compared to the previous year.

The Biofrontera EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-0.50 EUR
Jan 1, 2019
-1.12 EUR
Jan 1, 2020
-4.00 EUR
Jan 1, 2021
-0.36 EUR
Jan 1, 2022
4.65 EUR
Jan 1, 2023
2.43 EUR
Jan 1, 2024
-13.61 EUR
Jan 1, 2025
-11.84 EUR
The Biofrontera EV/EBITDA history
YEAREV/EBITDAYoY
-11.84-12.95%
-13.61-658.97%
2.43-47.64%
4.65-1,398.44%
-0.36-91.05%
-4.00+256.22%
-1.12+123.38%
-0.50-56.22%
-1.15+440.28%
-0.21-90.34%
-2.20+17.16%
-1.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

EV/EBITDA (Enterprise Value to EBITDA) of Biofrontera is -11.84 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Biofrontera changed from -13.61 to -11.84, representing a -12.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Biofrontera since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Biofrontera with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biofrontera

All Key Metrics — Biofrontera